Ellen Burnham
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 39 | 2025 | 814 | 6.530 |
Why?
| | Respiratory Insufficiency | 11 | 2026 | 333 | 2.070 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 644 | 1.920 |
Why?
| | Intensive Care Units | 21 | 2025 | 905 | 1.840 |
Why?
| | Lung | 19 | 2025 | 4143 | 1.690 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 121 | 1.630 |
Why?
| | Cannabis | 5 | 2025 | 517 | 1.290 |
Why?
| | Pneumonia | 9 | 2023 | 641 | 1.270 |
Why?
| | Ethanol | 11 | 2022 | 626 | 1.240 |
Why?
| | Acute Lung Injury | 10 | 2022 | 308 | 1.230 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 326 | 1.200 |
Why?
| | Critical Illness | 21 | 2024 | 880 | 1.140 |
Why?
| | Hospitalization | 10 | 2025 | 2340 | 1.100 |
Why?
| | Marijuana Smoking | 3 | 2025 | 257 | 1.080 |
Why?
| | Sepsis | 6 | 2020 | 639 | 1.050 |
Why?
| | Gene Expression | 3 | 2020 | 1512 | 1.000 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 372 | 0.990 |
Why?
| | Patient Admission | 2 | 2025 | 206 | 0.990 |
Why?
| | Cytokines | 9 | 2025 | 2093 | 0.940 |
Why?
| | Middle Aged | 75 | 2026 | 35630 | 0.920 |
Why?
| | Critical Care | 10 | 2021 | 693 | 0.910 |
Why?
| | Survivors | 8 | 2025 | 513 | 0.880 |
Why?
| | Inflammation Mediators | 4 | 2016 | 511 | 0.860 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 83 | 0.820 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 390 | 0.810 |
Why?
| | Adult | 68 | 2025 | 40129 | 0.810 |
Why?
| | Acetates | 2 | 2021 | 82 | 0.810 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 65 | 0.800 |
Why?
| | Stem Cells | 5 | 2015 | 622 | 0.780 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 176 | 0.780 |
Why?
| | Humans | 133 | 2026 | 143821 | 0.770 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 395 | 0.760 |
Why?
| | Hospital Mortality | 7 | 2025 | 975 | 0.750 |
Why?
| | Smoking | 8 | 2021 | 1556 | 0.750 |
Why?
| | Mentors | 4 | 2014 | 214 | 0.750 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 184 | 0.750 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 580 | 0.740 |
Why?
| | Lung Diseases | 3 | 2021 | 794 | 0.720 |
Why?
| | Male | 83 | 2026 | 71569 | 0.710 |
Why?
| | Female | 85 | 2026 | 77570 | 0.700 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 272 | 0.690 |
Why?
| | Behavior | 1 | 2021 | 90 | 0.660 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 215 | 0.650 |
Why?
| | Thalamus | 2 | 2021 | 121 | 0.650 |
Why?
| | Glycerophospholipids | 4 | 2024 | 36 | 0.640 |
Why?
| | Case-Control Studies | 14 | 2022 | 3614 | 0.640 |
Why?
| | Respiration, Artificial | 13 | 2025 | 706 | 0.630 |
Why?
| | Burnout, Professional | 4 | 2022 | 477 | 0.610 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1079 | 0.600 |
Why?
| | Hallucinogens | 1 | 2021 | 110 | 0.600 |
Why?
| | Cigarette Smoking | 2 | 2020 | 104 | 0.580 |
Why?
| | RNA, Messenger | 5 | 2020 | 2847 | 0.560 |
Why?
| | Glutathione | 5 | 2016 | 379 | 0.560 |
Why?
| | Antioxidants | 4 | 2016 | 580 | 0.560 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.550 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 310 | 0.540 |
Why?
| | Tobacco Products | 1 | 2019 | 89 | 0.540 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 582 | 0.540 |
Why?
| | Epithelial Cells | 4 | 2021 | 1128 | 0.540 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 123 | 0.540 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 24 | 0.530 |
Why?
| | Physicians, Women | 1 | 2019 | 87 | 0.530 |
Why?
| | Inflammation | 8 | 2025 | 2893 | 0.520 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 92 | 0.520 |
Why?
| | Biomedical Research | 2 | 2021 | 709 | 0.490 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 277 | 0.490 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 12 | 0.480 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 52 | 0.480 |
Why?
| | Marijuana Abuse | 1 | 2018 | 211 | 0.470 |
Why?
| | Alcohol Drinking | 6 | 2025 | 831 | 0.460 |
Why?
| | Aged | 35 | 2026 | 25615 | 0.460 |
Why?
| | Retrospective Studies | 25 | 2025 | 16754 | 0.450 |
Why?
| | Burns | 4 | 2024 | 365 | 0.450 |
Why?
| | Azithromycin | 1 | 2015 | 104 | 0.440 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.430 |
Why?
| | Electric Impedance | 2 | 2025 | 113 | 0.430 |
Why?
| | Research Support as Topic | 2 | 2011 | 79 | 0.410 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1075 | 0.410 |
Why?
| | Hypoxia | 4 | 2026 | 1199 | 0.410 |
Why?
| | Professional Autonomy | 1 | 2013 | 32 | 0.410 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 176 | 0.400 |
Why?
| | Cells, Cultured | 8 | 2018 | 4172 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2782 | 0.390 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 873 | 0.390 |
Why?
| | Bronchoscopy | 3 | 2023 | 227 | 0.380 |
Why?
| | Oxidative Stress | 5 | 2017 | 1377 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2018 | 853 | 0.370 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 22 | 0.360 |
Why?
| | Asthma | 2 | 2022 | 1915 | 0.360 |
Why?
| | Biomarkers | 15 | 2026 | 4248 | 0.350 |
Why?
| | Academic Medical Centers | 2 | 2014 | 537 | 0.350 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 281 | 0.340 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 577 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 330 | 0.330 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2620 | 0.320 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.310 |
Why?
| | United States | 18 | 2026 | 15602 | 0.310 |
Why?
| | Malondialdehyde | 2 | 2021 | 30 | 0.310 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2017 | 112 | 0.310 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 98 | 0.310 |
Why?
| | Personnel Selection | 1 | 2011 | 91 | 0.310 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 81 | 0.300 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 104 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 5861 | 0.290 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1901 | 0.290 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 125 | 0.290 |
Why?
| | Prevalence | 4 | 2025 | 2819 | 0.290 |
Why?
| | Smokers | 2 | 2021 | 148 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 97 | 0.270 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.270 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 238 | 0.270 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.260 |
Why?
| | Sexism | 2 | 2019 | 70 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 154 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.260 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1223 | 0.250 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 190 | 0.250 |
Why?
| | Pilot Projects | 6 | 2025 | 1851 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1508 | 0.250 |
Why?
| | Naltrexone | 2 | 2025 | 118 | 0.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 238 | 0.250 |
Why?
| | Deglutition Disorders | 3 | 2013 | 149 | 0.250 |
Why?
| | Fibronectins | 1 | 2007 | 136 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1322 | 0.240 |
Why?
| | Endothelial Cells | 4 | 2011 | 858 | 0.240 |
Why?
| | APACHE | 4 | 2013 | 65 | 0.240 |
Why?
| | Young Adult | 13 | 2024 | 13914 | 0.240 |
Why?
| | Marijuana Use | 2 | 2022 | 216 | 0.240 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 170 | 0.230 |
Why?
| | Administration, Inhalation | 3 | 2025 | 592 | 0.230 |
Why?
| | Preoperative Care | 1 | 2008 | 376 | 0.230 |
Why?
| | Immunity, Cellular | 2 | 2018 | 273 | 0.230 |
Why?
| | Risk Factors | 16 | 2020 | 10623 | 0.230 |
Why?
| | Pediatrics | 1 | 2013 | 1080 | 0.230 |
Why?
| | Anesthesiology | 1 | 2008 | 169 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 8 | 0.230 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1174 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 54 | 0.230 |
Why?
| | Arachidonic Acids | 1 | 2025 | 48 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 385 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 382 | 0.220 |
Why?
| | Flow Cytometry | 2 | 2024 | 1192 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 50 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 89 | 0.220 |
Why?
| | Endocannabinoids | 1 | 2025 | 57 | 0.210 |
Why?
| | Immunity | 1 | 2025 | 139 | 0.210 |
Why?
| | Dysbiosis | 2 | 2024 | 186 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 61 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 872 | 0.200 |
Why?
| | Bacterial Proteins | 1 | 2010 | 928 | 0.200 |
Why?
| | Patient Discharge | 3 | 2024 | 939 | 0.200 |
Why?
| | Quality of Life | 2 | 2013 | 3142 | 0.200 |
Why?
| | Anticoagulants | 2 | 2019 | 718 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 327 | 0.200 |
Why?
| | Drug Prescriptions | 1 | 2025 | 269 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 396 | 0.200 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.200 |
Why?
| | Aged, 80 and over | 10 | 2022 | 8130 | 0.200 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 206 | 0.190 |
Why?
| | Internship and Residency | 1 | 2013 | 1245 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 257 | 0.190 |
Why?
| | Lung Injury | 2 | 2016 | 227 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 193 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 22 | 0.180 |
Why?
| | Epithelium | 2 | 2021 | 316 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 30 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3288 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 434 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 104 | 0.170 |
Why?
| | Interleukin-8 | 3 | 2018 | 273 | 0.170 |
Why?
| | Double-Blind Method | 4 | 2014 | 2017 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Fibroblasts | 3 | 2013 | 1035 | 0.170 |
Why?
| | Societies, Medical | 2 | 2025 | 865 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 324 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Interleukin-6 | 3 | 2026 | 791 | 0.170 |
Why?
| | Feces | 1 | 2024 | 506 | 0.160 |
Why?
| | Neutrophils | 3 | 2017 | 1144 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 638 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 297 | 0.160 |
Why?
| | Physicians | 3 | 2022 | 932 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 364 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1675 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 345 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1638 | 0.160 |
Why?
| | Capacity Building | 1 | 2020 | 59 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2021 | 218 | 0.160 |
Why?
| | Animals | 18 | 2025 | 38140 | 0.160 |
Why?
| | Permeability | 2 | 2012 | 168 | 0.150 |
Why?
| | Career Choice | 2 | 2012 | 236 | 0.150 |
Why?
| | Chemokines | 2 | 2018 | 224 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1135 | 0.150 |
Why?
| | Cardiology | 1 | 2022 | 287 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 85 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 638 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 98 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2022 | 294 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 395 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 965 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2901 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 431 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2006 | 949 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2446 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 176 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 612 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 84 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 375 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Length of Stay | 4 | 2020 | 1312 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 46 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 967 | 0.140 |
Why?
| | Hospitals, University | 2 | 2015 | 175 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 115 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 250 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 112 | 0.130 |
Why?
| | Pyrazoles | 1 | 2001 | 499 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 962 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 189 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 991 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 64 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 165 | 0.130 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 481 | 0.130 |
Why?
| | Cystine | 1 | 2016 | 18 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2018 | 311 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2026 | 1065 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 559 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 99 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11459 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 843 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4553 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 341 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 746 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5316 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 265 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 285 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 278 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 181 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 328 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1023 | 0.110 |
Why?
| | Inflammasomes | 1 | 2017 | 147 | 0.110 |
Why?
| | Hospitals | 1 | 2020 | 695 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Patient Selection | 2 | 2023 | 695 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2017 | 243 | 0.110 |
Why?
| | Cysteine | 1 | 2016 | 210 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 191 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 141 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 178 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 398 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 681 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 282 | 0.110 |
Why?
| | Prospective Studies | 7 | 2026 | 7900 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5241 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1096 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 152 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2926 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 61 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 21 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1260 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1047 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2266 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 96 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 77 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 42 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 33 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 421 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 401 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 41 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3392 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 76 | 0.100 |
Why?
| | Financial Support | 1 | 2012 | 17 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2871 | 0.090 |
Why?
| | Logistic Models | 5 | 2017 | 2095 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1268 | 0.090 |
Why?
| | Interleukin-12 | 1 | 2013 | 121 | 0.090 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 23 | 0.090 |
Why?
| | Aging | 2 | 2017 | 1968 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1110 | 0.090 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1504 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 62 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 198 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 49 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 311 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 996 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 86 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 89 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 164 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 76 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3834 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 570 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 856 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 699 | 0.080 |
Why?
| | Capillaries | 2 | 2009 | 124 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 475 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1121 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 83 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 15 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 280 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 70 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 467 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1497 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 607 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 2045 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 162 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4578 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1525 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 250 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 240 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 368 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Mice | 7 | 2022 | 18421 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 427 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Computers | 1 | 2008 | 68 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 113 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6032 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 150 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1981 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 573 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 94 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 314 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 336 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2030 | 0.070 |
Why?
| | Schools | 1 | 2011 | 457 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 191 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 148 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 28 | 0.060 |
Why?
| | Cell Separation | 3 | 2016 | 311 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2007 | 107 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2007 | 78 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 128 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 449 | 0.060 |
Why?
| | Georgia | 2 | 2004 | 86 | 0.060 |
Why?
| | Sex Factors | 1 | 2013 | 2078 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 394 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 724 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 151 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 71 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 208 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 947 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1141 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 190 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 156 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 96 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 663 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5761 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 113 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 359 | 0.060 |
Why?
| | Louisiana | 1 | 2024 | 26 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 2041 | 0.050 |
Why?
| | Observation | 1 | 2004 | 51 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22233 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 209 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 799 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 142 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1459 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2902 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 7068 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6004 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 351 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 36 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 25 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 78 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 56 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 77 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 83 | 0.040 |
Why?
| | North America | 1 | 2022 | 309 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 144 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 193 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 6 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 360 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 246 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 173 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3120 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 674 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 21 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 878 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1355 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5609 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 62 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 445 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2845 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4210 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 327 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 22 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1826 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 170 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 346 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2018 | 135 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 46 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 404 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1626 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3183 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 165 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 90 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 705 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 841 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1402 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 767 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 194 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1843 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 337 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 379 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2948 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 125 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 157 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 31 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2894 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 325 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 184 | 0.030 |
Why?
| | Risk | 1 | 2018 | 901 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 136 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 454 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 262 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 461 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 522 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 946 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 561 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 250 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 212 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1252 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 828 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2097 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 957 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 26 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 330 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2013 | 39 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1358 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1011 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 26 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 317 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 412 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 112 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 547 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 138 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 148 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 747 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 524 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 353 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 66 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 700 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2261 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2522 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 514 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 103 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 92 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 427 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 207 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 185 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 563 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1192 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 102 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 838 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 272 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1751 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 573 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 56 | 0.020 |
Why?
| | Amides | 1 | 2010 | 101 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 598 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 464 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 387 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 45 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 721 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1761 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 233 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1817 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1068 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 165 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 30 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 49 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 22 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 49 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 87 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 983 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 62 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 80 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 47 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 31 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 81 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 269 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 68 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 258 | 0.020 |
Why?
| | Child | 2 | 2022 | 22440 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1044 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 476 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 509 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 973 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 357 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 238 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1833 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 563 | 0.010 |
Why?
| | Adipocytes | 1 | 2008 | 221 | 0.010 |
Why?
| | Trauma Centers | 1 | 2009 | 462 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 340 | 0.010 |
Why?
| | Cell Lineage | 1 | 2008 | 376 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1688 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 231 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 248 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 564 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1502 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 416 | 0.010 |
Why?
| | France | 1 | 2003 | 39 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 84 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 986 | 0.010 |
Why?
| | Washington | 1 | 2003 | 161 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 179 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2540 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1308 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|